ArticleCurrent therapeutic research, clinical and experimental2019
Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach.
Article in Current therapeutic research, clinical and experimental, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Development of a Disease-Specific Virtual Malaria Population for Physiologically-Based Pharmacokinetic Modeling.CPT: pharmacometrics & systems pharmacology · 2026Article
- Medicinal Plants and the Gastrointestinal Microbiota in Chronic Diseases Modulation: A Structured Mechanistic and Translational Review.Current microbiology · 2026Review
- Unlocking the Secrets of Nature: Phytochemicals as Key Players in Longevity and Healthy Aging.Cell biochemistry and biophysics · 2026Review
- Endogenous Plant signals and human Health: Molecular mechanisms, ecological functions, and therapeutic Prospects.Biochemistry and biophysics reports · 2025Review
- Phytochemicals as modulators of ferroptosis: a novel therapeutic avenue in cancer and neurodegeneration.Molecular biology reports · 2025Review
- Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.International journal of molecular sciences · 2023Review
- Determinants of Patients' Adherence to Malaria Treatment in the Democratic Republic of the Congo.Tropical medicine and infectious disease · 2022Article
- Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.Future microbiology · 2021Article
- Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.Clinical pharmacology : advances and applications · 2021Review
- Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.Travel medicine and infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe varied disposition of the antimalarial quinine partly explains its poor tolerance and toxicity in humans.
objectiveUsing a population approach, the disposition of quinine in healthy subjects and patients with acute uncomplicated symptomatic malaria from Nigeria was re-examined with a view to providing population-specific attributes.
methodsConcentration versus time profiles of quinine over 48 hours in healthy individuals, and over 7 days in malaria-infected patients, were stratified to reflect: concentration versus time data during the first 48 hours of quinine administration for healthy subjects and infected patients, concentration versus time data after 48 hours in infected patients, and all concentration versus time data available for healthy subjects and infected patients. Pharmacokinetic parameters were then estimated with a stochastic approximation expectation maximization algorithm.
resultsAll datasets were fitted by a 1-compartment model with covariate contributions from body weight and infection status. The absorption rate constant, and volume of distribution and clearance were 1.72 h
conclusionsThe study findings suggest that clinical interventions aimed at enhancing the safety and tolerance of quinine might be achieved by a rational decrease in dose size and/or dosing interval, post-48 hours of chronic quinine administration, in malaria-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.